RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-4.85%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.16B
AUM Growth
-$97.2M
Cap. Flow
+$7.64M
Cap. Flow %
0.66%
Top 10 Hldgs %
55.45%
Holding
63
New
12
Increased
17
Reduced
17
Closed
13
Avg Time Held
1 year
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$27.1M
2
PEN icon
Penumbra
PEN
+$24.6M
3
ESRX
Express Scripts Holding Company
ESRX
+$24.3M
4
XNCR icon
Xencor
XNCR
+$24M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$20.5M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$39.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$23.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$21.6M
4
ELGX
Endologix Inc
ELGX
+$20.8M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$20.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.86%
2 Miscellaneous 1.19%
3 Financials 0.92%
4 Communication Services 0.62%
5 Consumer Staples 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PTHN
26
DELISTED
Patheon N.V.
PTHN
$12.7M 1.09%
+440,720
New +$12.2M
2016 Q4
0 quarters
SYRS icon
27
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$11.5M 0.99%
94,844
+5,566
+6% +$780K
2016 Q2
2 quarters
ELV icon
28
Elevance Health
ELV
$92.8B
$11.1M 0.96%
+77,223
New +$10.3M
2016 Q4
0 quarters
EHTH icon
29
eHealth
EHTH
$19.5M
$10.6M 0.92%
+997,621
New +$10.2M
2016 Q4
0 quarters
BSX icon
30
Boston Scientific
BSX
$62.3B
$9.94M 0.86%
459,505
-613,133
-57% -$13.4M
2015 Q4
4 quarters
NVTA
31
DELISTED
Invitae Corporation
NVTA
$8.46M 0.73%
1,065,002
+554,633
+109% +$4.15M
2015 Q1
7 quarters
PRQR icon
32
ProQR Therapeutics
PRQR
$207M
$7.73M 0.67%
1,578,174
+1,002,311
+174% +$5.16M
2014 Q3
9 quarters
CTMX icon
33
CytomX Therapeutics
CTMX
$486M
$7.66M 0.66%
696,992
-17,700
-2% -$214K
2015 Q4
4 quarters
MODN icon
34
DELISTED
MODEL N, INC.
MODN
$7.17M 0.62%
809,914
-741,045
-48% -$6.89M
2013 Q4
12 quarters
ELGX
35
DELISTED
Endologix Inc
ELGX
$6.9M 0.6%
120,689
-227,375
-65% -$20.8M
2015 Q4
4 quarters
IRTC icon
36
iRhythm Holdings
IRTC
$3.5B
$6.86M 0.59%
+228,800
New +$6.16M
2016 Q4
0 quarters
WOOF icon
37
DELISTED
VCA Inc.
WOOF
$4.81M 0.41%
70,040
-20,960
-23% -$1.37M
2016 Q1
3 quarters
SPNC
38
DELISTED
Spectranetics Corp
SPNC
$4.6M 0.4%
187,627
-147,114
-44% -$3.46M
2016 Q2
2 quarters
GBT
39
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.57M 0.39%
+316,400
New +$5.56M
2016 Q4
0 quarters
DVAX icon
40
DELISTED
Dynavax Technologies
DVAX
$4.15M 0.36%
+1,049,791
New +$7.69M
2016 Q4
0 quarters
FATE icon
41
Fate Therapeutics
FATE
$232M
$3.56M 0.31%
1,419,058
-6,100
-0.4% -$16.3K
2015 Q2
6 quarters
RARX
42
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.74M 0.24%
+180,310
New +$2.45M
2016 Q4
0 quarters
ACRS icon
43
Aclaris Therapeutics
ACRS
$498M
$2.56M 0.22%
+94,200
New +$2.4M
2016 Q4
0 quarters
DPLO
44
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$1.93M 0.17%
+153,317
New +$2.86M
2016 Q4
0 quarters
IBB icon
45
iShares Biotechnology ETF
IBB
$10.4B
$1.19M 0.1%
+13,500
New +$1.23M
2016 Q4
0 quarters
UNH icon
46
UnitedHealth
UNH
$355B
$291K 0.03%
1,820
– –
2016 Q3
1 quarter
AUPH icon
47
Aurinia Pharmaceuticals
AUPH
$2.21B
$77K 0.01%
36,743
-150,867
-80% -$485K
2015 Q4
4 quarters
ADVM icon
48
DELISTED
Adverum Biotechnologies
ADVM
$64K 0.01%
2,224
– –
2016 Q2
2 quarters
CSLT
49
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$51K ﹤0.01%
10,229
– –
2016 Q2
2 quarters
AZN icon
50
AstraZeneca
AZN
$251B
– –
-144,178
Closed -$9.47M –
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2016 Portfolio in Review

As of Q4 2016, Redmile Group held 63 positions worth $1.16B, down 7.7% from $1.26B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group's Q4 2016 filing shows 12 new, 17 increased, 17 reduced and 13 closed positions. Its largest new stake was Express Scripts Holding Company: 338,800 shares worth $23.3M. The largest sale was Sarepta Therapeutics, an estimated $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q4 2016 buy was Express Scripts Holding Company: 338,800 shares worth $23.3M.
  • Redmile Group added most to Puma Biotechnology in Q4 2016, an estimated $27.1M increase.
  • Redmile Group's biggest Q4 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $21.6M.
  • Redmile Group fully exited Sarepta Therapeutics in Q4 2016, selling an estimated $39.3M.
  • Redmile Group's ten largest holdings make up 55% of its $1.16B portfolio in Q4 2016.
  • Redmile Group opened 12 new positions and closed 13 in Q4 2016.
  • Redmile Group's portfolio value fell 7.7% quarter-over-quarter to $1.16B.

Based on Redmile Group's 13F filing for Q4 2016, filed 14 Feb 2017.